Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus

Circulation

Volumn 124, Issue 8, 2011, Pages 893-900

  Stone, Gregg W ^a   Kedhi, Elvin ^b   Kereiakes, Dean J ^c   Parise, Helen ^a   Fahy, Martin ^a   Serruys, Patrick W ^d   Smits, Pieter C ^b  

^a Department of Medicine   (United States)

^b Maasstad Hospital   (Netherlands)

^c The Carl & Edyth Lindner Center for Research & Education   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

coronary artery disease; diabetes mellitus; prognosis; restenosis; stents

Indexed keywords

EVEROLIMUS; INSULIN; PACLITAXEL;

CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STENT THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; TUBULIN MODULATORS;

EID: 80052147450     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.031070     Document Type: Review

References (20)

1. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schömig A. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998; 32:1866-1873. (Pubitemid 29010448)
2. Singh M, Gersh BJ, McClelland RL, Ho KK, Willerson JT, Penny WF, Holmes DR Jr. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial. Circulation. 2004;109:2727-2731. (Pubitemid 38737919)
3. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009; 119:3198-3206.
4. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114:798-806. (Pubitemid 44268230)
5. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, Russell ME, Ellis SG, Mehran R, Stone GW; TAXUS-IV Investigators. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1172-1179. (Pubitemid 40523133)
6. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004;109:2273-2278. (Pubitemid 38678518)
7. Dawkins KD, Stone GW, Colombo A, Grube E, Ellis SG, Popma JJ, Serruys PW, Lam P, Koglin J, Russell ME. Integrated analysis of medically treated diabetic patients in the TAXUS(R) program: benefits across stent platforms, paclitaxel release formulations, and diabetic treatments. EuroIntervention. 2006;2:61-68.
8. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP; REALITY Trial Investigators. Sirolimus-vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006;295:895-904.
9. Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schömig A; ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-670. (Pubitemid 41175674)
10. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrié D, Thuesen L, Boone E, Miquel-Herbert K, Daemen J. A randomised comparison of an everolimuseluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention. 2006;2:286-294.
11. Claessen BE, Beijk MA, Legrand V, Ruzyllo W, Manari A, Varenne O, Suttorp MJ, Tijssen JG, Miquel-Hebert K, Veldhof S, Henriques JP, Serruys PW, Piek JJ. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. Circ Cardiovasc Interv. 2009;2:339-347.
12. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903-1913. (Pubitemid 351574920)
13. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation. 2009;119:680-686.
14. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010; 362:1663-1674.
15. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxeleluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201-209.
16. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical endpoints in coronary stent trials-a case for standardized definitions. Circulation. 2007;115:2344-2351. (Pubitemid 46685903)
17. Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res. 2000;60:5390-5394.
18. Rocic P. Differential phosphoinositide 3-kinase signaling: implications for PTCA? Am J Physiol Heart Circ Physiol. 2009;297:H1970-H1971.
19. Stone GW, Ellis SG, Colombo A, Dawkins KD, Grube E, Cutlip DE, Friedman M, Baim DS, Koglin J. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation. 2007; 115:2842-2847. (Pubitemid 46869671)
20. Zhang F, Dong L, Ge J. Meta-analysis of five randomized clinical trials comparing sirolimus-versus paclitaxel-eluting stents in patients with diabetes mellitus. Am J Cardiol. 2010;105:64-68.